Delayed cardiac toxicity from anthracycline therapy.
Survivors of childhood cancer who received anthracycline treatment have a high incidence of abnormal cardiac function. Cardiac decompensation and death can appear many years after completion of chemotherapy. These survivors require periodic evaluation of cardiac function and rhythm.
Steinherz
L
L
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Steinherz
P
P
D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D002648:Child; D003630:Daunorubicin / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D005500:Follow-Up Studies; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy
D004317:Doxorubicin; D003630:Daunorubicin